POZN (10.21)…clinical data is extremely strong! Clinical efficacy and safety endpoints have been met per SPA with the FDA images.investorshub.advfn.com/images/uploads/2010/3/22/wqcsrPrev_of_low_dose_asprin_w_Esomeprazole.JPG images.investorshub.advfn.com/images/uploads/2010/3/22/gontxPrev_of_low_dose_asprin_w_Esomeprazole_2.JPG images.investorshub.advfn.com/images/uploads/2010/3/22/cicxpPrev_of_low_dose_asprin_w_Esomeprazole_3.JPG images.investorshub.advfn.com/images/uploads/2010/3/22/ngqsoPrev_of_low_dose_asprin_w_Esomeprazole_4.JPG images.investorshub.advfn.com/images/uploads/2010/3/22/jmuonPN400.JPG images.investorshub.advfn.com/images/uploads/2010/3/27/tnqxhWhat_is_VIMOVO.JPG